The Leukemia & Lymphoma Societyinc
The Leukemia & Lymphoma Society (now operating as Blood Cancer United) is a 501(c)(3) nonprofit organization headquartered in Washington, DC, with additional offices in Rye Brook, New York. Founded in 1949, the organization is the largest nonprofit funder of blood cancer research globally. The organization employs 1,228 staff members and operates in the United States, Canada, and nine additional countries including the United Kingdom, Argentina, Puerto Rico, and Brazil.
Financial Overview
From 2024 IRS Form 990-PF · View filing
Total Assets
$602.0M
-6.5% YoY
Annual Giving
$52.3M
+8.2% YoY
Grant Count
69
-9.2% YoY
Avg Grant Size
$757K
+19.2% YoY
Mission & Focus Areas
Mission Statement: Cure blood cancer and improve the quality of life of all patients and their families.
The organization operates across three primary strategic areas:
Research Programs: The organization funds groundbreaking blood cancer research across the entire research continuum, from basic laboratory science through clinical trials to private-sector drug development partnerships. The organization has invested over $1.8 billion in research to date and has been instrumental in advancing 75% of nearly 100 new blood cancer treatment approvals over the past five years. Current research priorities include precision medicine, immunotherapy, and investigation of links between mutations and blood cancer. The organization has supported notable advances including Chimeric Antigen Receptor T cell (CAR T) therapy, which has produced cures for some patients who have exhausted other treatment options.
Policy & Advocacy: The organization's Policy & Advocacy team works to remove barriers to care through grassroots mobilization and advocacy to influence state and federal laws and regulations. The team focuses on ensuring all blood cancer patients have access to needed treatments and care.
Patient Support & Services: The organization provides disease information, treatment resources, support services, and educational resources for patients and families affected by blood cancer.
Grantmaking
The organization has committed significant funding to research initiatives:
Ready to take the next step with The Leukemia & Lymphoma Societyinc?
Geographic Focus
Where this funder awards grants
The organization funds research and provides services in the United States and internationally, including Canada, the United Kingdom, Argentina, Puerto Rico, Brazil, and nine additional countries.
Grant Distribution by State
States
Cities
Financial History
Multi-year comparison from IRS filings
Fiscal Year 2024:
- Total Revenue: $368,242,059
- Total Expenses: $371,792,172
- Total Assets: $602,010,519
- Total Liabilities: $211,000,000
Tax Status: Tax-exempt since January 2001 (EIN: 13-5644916)
Organizational Rating: The organization holds a Four-Star rating from independent charity evaluators, with a 99% overall score based on Impact & Measurement (47%), Accountability & Finance (38%), Leadership & Adaptability (10%), and Culture & Community (5%).
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Assets | $602,010,519 | $643,891,871 | $693,676,206 |
| Revenue | $368,242,059 | $378,338,490 | $426,997,204 |
| Expenses | $371,792,172 | $386,072,968 | $518,622,394 |
| Qualifying Distributions | — | — | — |
| Net Investment Income | $16,623,882 | $15,134,480 | $6,919,696 |
| Distributable Amount | — | — | — |
Giving Over Time
Total grant dollars and number of grants per year
Grant Insights
How this funder distributes its grants
Top Recipients
Top 10 recipients in 2024
Grant Size Distribution
250 grants across all recorded years
Open Grants
6 open opportunities from The Leukemia & Lymphoma Societyinc
Career Development Program: Fellow Award Grant
THE LEUKEMIA & LYMPHOMA SOCIETYINC
Amount
US $65,000 - US $70,000
Deadline
Rolling / Open
Career Development Program: Scholar Grant
THE LEUKEMIA & LYMPHOMA SOCIETYINC
Amount
Up to US $120,000
Deadline
Rolling / Open
Career Development Program: Scholar in Clinical Research Grant
THE LEUKEMIA & LYMPHOMA SOCIETYINC
Amount
Up to US $125,000
Deadline
Rolling / Open
Giving History
Grant recipients and amounts by year
No grants recorded for .
Leadership & Key People
Leadership team and compensation from IRS filings
E. Anders Kolb, M.D. - President & CEO
Louis J. DeGennaro - President and CEO (referenced in organizational materials regarding the Four-Star rating achievement)
Compensation Overview
From 2024 IRS filing
From 2024 filing
| Name | Title | Hours | Compensation |
|---|---|---|---|
| JEFF SACHS | CHAIR | 4 | — |
| KATHLEEN MERIWETHER | VICE CHAIR | 4 | — |
| FREDA WANG | SECRETARY/TREASURER | 4 | — |
| JANICE GABRILOVE MD | AT LARGE | 4 | — |
| LEROY BALL | BOD MEMBER | 4 | — |
| RICHARD BAGGER | BOD MEMBER | 4 | — |
| MARK BAEEENECHEA | BOD MEMBER | 4 | — |
| RENZO CANETTA MD | BOD MEMBER | 4 | — |
| CASEY CUNNINGHAM MD | BOD MEMBER | 4 | — |
| HELEN HESLOP | BOD MEMBER | 4 | — |
| ARI MELNICK | BOD MEMBER | 4 | — |
| RUBEN MESA | BOD MEMBER | 4 | — |
| LYNNE O'BRIEN | BOD MEMBER | 4 | — |
| MARLA PERSKY | BOD MEMBER | 4 | — |
| JIM REDDOCH | BOD MEMBER | 4 | — |
| RICHARD RENDINA | BOD MEMBER | 4 | — |
| ROBERT ROSEN | BOD MEMBER | 4 | — |
| BART SICHEL | BOD MEMBER | 4 | — |
| ALESSANDRA TOCCO | BOD MEMBER | 4 | — |
| YVETTE TREMONTI | BOD MEMBER | 4 | — |
| E ANDERS KOLB - START 512023 | PRESIDENT & CEO | 40 | $471,613 |
| GWEN NICHOLS | EVP, CHIEF MEDICAL OFC | 40 | $526,284 |
| TROY DUNMIRE | EVP, CHIEF OPERATING OFC | 40 | $510,557 |
| DALE NISSENBAUM | EVP, GENERAL COUNSEL | 40 | $497,291 |
| GORDON MILLER JR | EVP, CHIEF FINANCIAL OFC | 40 | $453,172 |
| COKER POWELL | SVP, CHIEF DEVELOPMENT OFC | 40 | $388,870 |
| VANESSA WHITE | SVP, CHIEF ADVANCEMENT OFC | 40 | $380,333 |
| SUSAN BROWN | SVP, CHIEF DEI OFC | 40 | $382,991 |
| LEE GREENBERGER | SVP, CHIEF SCIENTIFIC OFC | 40 | $377,058 |
| FLORENCE GODFREY | SVP, CHIEF EXPERIENCE OFC | 40 | $341,009 |
| LOUIS JDEGENNARO-END 63023 | PRESIDENT & CEO - FORMER | 40 | $1,358,093 |
Recent News & Activity
Recent developments and announcements
The organization has announced multiple significant research funding commitments and partnerships:
Awarded $65 million in new funding for blood cancer research
The Leukemia & Lymphoma Society Awards $65 Million in New Funding for BloodCommitted $188 million to fuel next generation of cancer research
LLS Fuels Next Generation of Cancer Research Committing $188 MillionPartnered with Blood Cancer UK to award $4.25 million for research into prevention of leukemia
The Leukemia & Lymphoma Society Awards $65 Million in New Funding for BloodInvested $6.5 million in research investigating causes of inequitable access to blood cancer treatment and care
The Leukemia & Lymphoma Society Awards $65 Million in New Funding for BloodFunded immunotherapy studies demonstrating remarkable results in patients with acute lymphoblastic leukemia
Immunotherapy Study Funded by The Leukemia & Lymphoma Society DemonstratesThe organization maintains active engagement in policy advocacy and continues to expand research initiatives focused on precision medicine, immunotherapy, and addressing health disparities in blood cancer treatment and clinical trial participation.
LLS Fuels Next Generation of Cancer Research Committing $188 MillionSubject Areas
Focus areas based on grantmaking activity
Data last updated April 2026. Sourced from IRS Form 990-PF filings. Research dossier generated April 2026.
What could you do with The Leukemia & Lymphoma Societyinc on Grantable?
- Assess strategic fit with your organization
- Draft a tailored letter of inquiry
- Find open RFPs from this funder
- Monitor for new funding opportunities